Sanofi’s Uses Latecomer COVID Data To Highlight Bigger mRNA Strategy
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
You may also be interested in...
Coronavirus Notebook: Sanofi Under Pressure To Hand mRNA Vaccine To Africa, EMA OKs Booster Dose For Comirnaty
The European Medicines Agency says there is a possible link between the Janssen vaccine and rare cases of venous thromboembolism, and that immune thrombocytopenia should be added as an adverse reaction to the Janssen and AstraZeneca vaccines. The agency has also begun evaluating a marketing authorization application for Celltrion’s regdanvimab in COVID-19 patients.
VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.
Seqirus is pursuing self-amplifying RNA, a promising but more technically complex approach which could help it compete in the next generation of flu and pandemic vaccines.